<DOC>
	<DOCNO>NCT00029900</DOCNO>
	<brief_summary>This study determine safety toxicity increase dos arginine deiminase combine polyethylene glycol ( ADI-PEG ) patient nonresectable metastatic melanoma .</brief_summary>
	<brief_title>ADI-PEG Patients With Metastatic Melanoma</brief_title>
	<detailed_description>The use amino acid degrade enzyme derive microbial source proven effective mean control form cancer auxotrophic nonessential amino acid . Recently show human melanoma auxotrophic arginine . As arginine nonessential amino acid human , elimination may prove effective method control cancer . Laboratory study provide promising result arginine-degrading enzyme arginine deiminase ( ADI ) couple polyethylene glycol ( PEG ) enhance circulate half-life . In study , patient receive 3 intramuscular treatment ADI-SS PEG 4-week period . There 4 cohort patient receive different dose level . Pharmacokinetics , pharmacodynamics , safety toxicity , immunogenicity study perform .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm metastatic melanoma Nonresectable disease Measurable evaluable disease Progressive disease follow standard chemotherapy , radiotherapy , surgery , immunotherapy ; longer respond therapy Recovered prior surgery Karnofsky performance status 70 high Expected survival least 12 week Bilirubin le 2.0 mg/dL Albumin great 3.0 g/dL SGOT le 5 time upper limit normal ( ULN ) Alkaline phosphatase less 5 time ULN Ammonia le 55 microg/dL Glucose great 60 mg/dL Amylase le 1.5 time ULN Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Patients must use 2 form effective contraception Exclusion criterion : Prior therapy within past 4 week Ascites pleural effusion Significant cardiac disease ( i.e. , New York Heart Association class III IV heart disease ) Pregnant nursing Concurrent enrollment another IND study Serious infection require antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Polyethylene Glycol</keyword>
	<keyword>Arginine Deiminase</keyword>
</DOC>